Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03513757 · ClinicalTrials.gov registry record · Phase 4
Dexmedetomidine and Propofol for Pediatric MRI Sedation
A Phase 4 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT03513757: Completed Phase 4 study, sponsored by Medical College of Wisconsin.
NCT03513757 is a Phase 4 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 40 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03513757, a Phase 4 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia for MRI studies in young children (propofol). The drugs used for the MRI scan in this study will be chosen randomly. Half the patients will receive small doses of propofol and dexmedetomidine. The other half will receive propofol administered constantly throughout the scan. Other drugs that may be used include sevoflurane and nitrous oxide at the start of the sedation (for placing an intravenous), lidocaine (to reduce the pain of propofol injection) and glycopyrrolate (to prevent the heart rate from decreasing too low. The investigators will record 5 additional blood pressures and heart rates. If additional medications are required to complete the scan, the investigators will administer whatever is necessary. At the end of the study, the investigators will have an observer record the time it takes for participants to spontaneously open eyes , to be able to drink liquids and/or eat and to behave as before the study. Also, it is very important that the investigators find out from participants about changes in behavior, or if eating or sleeping habits were unusual following completion of the study. For that reason, the investigators will call participants in a day or so following the MRI scan. The investigators expect to recruit 40 children between the ages of 12 and 72 months for the study and hope to have the study completed in December 2018.
Primary Outcome
Time (minutes) from anesthesia start to readiness for discharge from the department to home or clinic.
Interventions
- DRUG Dexmedetomidine
- DRUG Nitrous Oxide
- DRUG Glycopyrrolate
- DRUG Lidocaine 1% Injectable Solution
- DRUG propofol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-03-04 |
| Est. Completion | 2018-10-21 |
| Phase | Phase 4 |
What the finished NCT03513757 record still lists
NCT03513757 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Dexmedetomidine is the first listed.
NCT03513757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03513757 about?
NCT03513757 is a clinical study titled "Dexmedetomidine and Propofol for Pediatric MRI Sedation". The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia for MRI studies in young children (propofol). The drugs used for the MRI...
What is the current status of trial NCT03513757?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2018-03-04. Estimated completion is 2018-10-21.
What interventions are being tested in trial NCT03513757?
The interventions under investigation include: Dexmedetomidine (DRUG), Nitrous Oxide (DRUG), Glycopyrrolate (DRUG), Lidocaine 1% Injectable Solution (DRUG), propofol (DRUG).
Who is sponsoring clinical trial NCT03513757?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03513757's enrollment target sits among peer trials
40 1397th of 2000 higher than 533 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI